StockNews.AI
CTKB
StockNews.AI
4 hrs

Cytek® Muse® Micro Cell Analyzer Wins BioTech Breakthrough Award for Drug Discovery Solution of the Year

1. Cytek's Muse Micro analyzer wins Drug Discovery Solution of the Year award. 2. Recognition by BioTech Breakthrough enhances Cytek's market reputation. 3. The Muse Micro system improves accessibility and cost-effectiveness in labs. 4. Favorable award may attract new customers and increase research funding. 5. Cytek continues to innovate with advanced cell analysis technologies.

11m saved
Insight
Article

FAQ

Why Bullish?

Industry awards can result in stock price increases based on enhanced visibility and credibility in the market. For example, Illumina experienced stock gains after product awards.

How important is it?

Recognition can strengthen Cytek’s position against competitors and lead to increased financial support.

Why Short Term?

Immediate recognition can lead to short-term price movements as investors react. Historical cases show quick gains after major award announcements.

Related Companies

ABCLSRGANVS
FREMONT, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) announced today that its Cytek® Muse® Micro cell analyzer has been named Drug Discovery Solution of the Year in the 2025 BioTech Breakthrough Awards. The annual program, conducted by leading independent market intelligence organization BioTech Breakthrough, recognizes innovative life sciences and biotechnology companies, products, and services worldwide. This year’s competition drew thousands of nominations from more than 15 countries. The award highlights Cytek’s commitment to making cell analysis more accessible, intuitive, and cost-effective for laboratories of all sizes. The Muse Micro cell analyzer builds on the legacy of the original Guava® Muse system, which revolutionized flow cytometry for thousands of laboratories. The enhanced Muse Micro system expands upon this proven success with extended capabilities to create an affordable, multifunctional system with a compact footprint that simplifies flow cytometry while delivering ease of use, accuracy, and versatility. Applications include cell counting, cell health and viability, apoptosis, immunophenotyping, immune cell monitoring, fluorescent protein analysis, and more. “With the Cytek Muse Micro cell analyzer, sophisticated cell analysis is no longer exclusive, complex, or expensive,” said Bryan Vaughn, managing director, BioTech Breakthrough. “Traditional flow cytometry systems are often all these things, restricting use to well-funded labs with extensive experience. Smaller labs, emerging markets, and resource-limited facilities find high-quality cell analysis to be inaccessible. The Muse Micro system combines affordability, compact design, and intuitive operation with advanced analytical capabilities, thereby lowering the financial and technical barriers to flow cytometry. For this important breakthrough, we’re awarding Cytek with the ‘Drug Discovery Solution of the Year’.”The mission of the annual BioTech Breakthrough Awards program is to conduct the industry’s most comprehensive analysis and evaluation of the world’s top companies, solutions and products in the life sciences and biotechnology markets today. “The Cytek Muse Micro cell analyzer furthers our mission of making high-quality flow cytometry more accessible,” said Wenbin Jiang, Ph.D., CEO of Cytek Biosciences. “In fact, the Muse Micro system is already demonstrating how a compact, cost-effective, and easy-to-use platform can simplify workflows and help laboratories of all sizes advance their research with greater efficiency and confidence.” For more information, please visit https://cytekbio.com/. About Cytek Biosciences, Inc. Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Muse® Micro system; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com. Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union). Cytek, Muse, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc. In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. These forward-looking statements include statements regarding Cytek’s mission, business plans and strategies. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include global geopolitical, economic and market conditions; Cytek’s ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek's ability to evaluate its prospects for future viability and predict future performance; Cytek’s ability to accurately forecast customer demand and adoption of its products; Cytek’s ability to recognize the anticipated benefits of collaborations; Cytek’s dependence on certain sole and single source suppliers; competition; market acceptance of Cytek’s current and potential products; Cytek’s ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek’s ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek’s ability to increase penetration in its existing markets and expand into adjacent markets; Cytek’s ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek’s ability to successfully develop and introduce new products; Cytek’s ability to maintain, protect and enhance its intellectual property; Cytek’s ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. You should refer to the section entitled “Risk Factors” set forth in Cytek’s Quarterly Report on Form 10-Q filed on November 5, 2025 with the SEC, and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek’s forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the events and circumstances reflected in the forward-looking statements will occur. The forward-looking statements in this press release are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek’s as of any date subsequent to the date of this press release. Media Contact:Stephanie OlsenLages & Associates(949) 453-8080stephanie@lages.com Investor Contact:Paul GoodsonHead of Investor RelationsCytek Biosciencespgoodson@cytekbio.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ce282ccb-5b7a-417f-abd1-52ab2d43bed4 BioTech Breakthrough Awards The Cytek® Muse® Micro cell analyzer has been named Drug Discovery Solution of the Year in the 2025 ...

Related News